Zimmer Biomet increases FY2026 share repurchase target to $1B, up $250M from prior view

ZIMMER BIOMET HOLDINGS, INC.

Now expects to repurchase up to $1.0B of common stock in FY2026, a $250M increase from prior assumption.
Repurchases will be made under existing $1.5B authorization approved by Board in February 2026.
No changes to size, duration or terms of the authorization.
May conduct open-market purchases or structured agreements; timing depends on market conditions, stock price, and capital availability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.